PAG
PDLI

Private Advisor Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Private Advisor Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,650
Closed -$14K – 3945
2020
Q2 		$14K Buy
+4,650
New +$14.7K ﹤0.01% 2779
2016
Q3 		– Sell
-13,064
Closed -$42K – 1214
2016
Q2 		$42K Buy
13,064
+418
+3% +$1.39K ﹤0.01% 1087
2016
Q1 		$42K Buy
+12,646
New +$39.4K ﹤0.01% 1003

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Private Advisor Group's PDLI Position: Q3 2020 in Review

Private Advisor Group sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 4,650 shares — an estimated $14K sold.

Private Advisor Group first reported a position in PDLI in Q1 2016 and held it in 3 quarters. The position peaked at $42K in Q2 2016. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • Private Advisor Group reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 4,650 PDL BioPharma, Inc. shares in Q3 2020, an estimated $14K.
  • Private Advisor Group first reported a position in PDL BioPharma, Inc. in Q1 2016 and held it in 3 quarters.
  • Private Advisor Group's PDL BioPharma, Inc. position peaked at $42K in Q2 2016.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.